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Abstract: Herbal and dietary supplement (HDS) use has grown exponentially in the United States.
Unfortunately, the incidence of HDS-related liver injury has proportionally increased. Despite the
potential for certain HDSs to cause clinically significant liver injury, they are not regulated by the
Food and Drug Administration. Recent efforts have been made to regulate HDSs but are far removed
from the scrutiny of prescription medications. Scant literature exists on HDSs and their risks of
causing liver injury. In this comprehensive review, we examine trends of HDS use in the United
States and the pathophysiologic mechanisms of drug-induced liver injury (DILI) of certain HDSs.
Finally, we review usage rates; benefits, if any; purported pathophysiology of DILI; and propensity
for progression to fulminant hepatic failure of nine HDSs linked to clinically significant DILI.
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1. Introduction
Consumer interest in herbal dietary supplements (HDSs) as alternative forms of or
supplements to conventional medication has increased over the last three decades. The
number of HDSs marketed in the United States (US) increased from around 4000 in 1993 to
55,000 in 2012 and continues to grow [1]. According to the CDC, in 2017–2018, 57.6% of
adults 20 years old and over reported using HDSs in the past 30 days. HDS use increased
with age, as did simultaneous use of multiple HDSs. One quarter of adults 60 years old
or older reported taking four or more HDSs; women within that age range were the most
likely to use HDSs, at 80.2%. From 2007 to 2018, HDS use increased in all age groups among
US adults [2].
Although already on the rise in recent years, HDSs have become even more popular
after emerging as potential adjunct therapies for COVID-19. A systematic review of
12 randomized control trials found that the consumption of HDSs and zinc sulfate may
significantly benefit COVID-19 recovery, although these studies also recognized the low
quality of the included trials [3]. These results were inconsistent with other previously
published reviews [3].
Despite a lack of evidence that HDSs benefit COVID-19, consumers were drawn to
these products to enhance their immune systems. After vitamin and mineral supplements,
turmeric, elderberry, garlic, and echinacea were the top ingredients used for immunity [4].
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Over 43% of HDS users increased their supplement regimen during the pandemic and
were more likely to practice healthy lifestyle habits than their non-supplement-using
counterparts [4,5]. Supplement users who were male, aged 18–34, had children in the
house, or who were seasonal users altered their routine during COVID-19 more than other
groups [4]. HDSs were used as both preventative and therapeutic treatments by consumers.
Although there has not yet been an equivalent study in the US, a cross-sectional study of
Saudi Arabian patients’ HDS use before and during COVID-19 infection found a significant
increase in patients using black seed and ginger [6].
Consumer interest was so strong during the pandemic that HDS sales in the US
surpassed USD 10 billion for the first time in 2020, totaling roughly USD 11.261 billion, a
17.3% increase from 2019 [7]. Equally, both US retail channels, mainstream and natural,
showed an increased profit margin. Mainstream channels are defined as mass market
channels such as convenience and grocery stores. Natural channels are defined as natural
health food specialty retail outlets. Consumers cited overall health, immune health, and
cardiovascular health as their top reasons for HDS use [7]. Elderberry, apple cider vinegar,
and ashwagandha sales increased most from the year prior, and elderberry, horehound, and
cranberry were the top-selling HDSs of mainstream multi-outlet channels in the US [7]. The
high epidemiological burden of stress, anxiety disorders, and sleep disorders due to COVID19 likely popularized the stress-reducing and sleep-inducing effects of HDSs [8]. The rise in
sales suggests increased acceptance and favorable views of HDSs by the American public,
who were willing to embrace alternative treatments given the unprecedented nature of
the pandemic.
2. Regulation of HDS
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the
Food and Drug Administration (FDA) is not required to review or approve HDSs for
safety or efficacy before they are marketed [9]. Individual HDS manufacturers are only
required to notify the FDA before marketing their products if the HDS contains a new
dietary ingredient, defined as any dietary ingredient marketed after 1994 [9]. Otherwise,
individual HDS manufacturers are responsible for determining the safety, dietary ingredient
composition, and appropriate serving size of HDSs without any oversights [9]. Individual
HDS manufacturers are also allowed to market HDSs with non-specific claims and benefits,
such as weight loss and liver support, without documented evidence [10].
Federal law requires individual HDS manufacturers to label HDSs as food supplements and provide a full list of dietary ingredients [9]. Despite this requirement, however,
many HDSs have been recalled for containing contaminated ingredients or dietary ingredients that are different from those listed on the product label [11]. Quality analysis
studies have demonstrated the contamination of HDSs with various heavy metals and
pesticides [12]. A recent study investigated the accuracy of dietary ingredient labels on
HDSs and found a mislabeling rate of 51% [13]. All of the mislabeled HDSs in this study
lacked one or more of the compounds listed on the dietary ingredient label, and some
also contained one or more compounds not listed on the dietary ingredient label [13].
Mislabeling rates were highest among HDSs marketed as weight loss supplements and
those with appearance- and performance-related claims [13].
The implications of HDS mislabeling and contamination include adverse events such
as hepatotoxicity. Cases of HDS-induced liver injury after the consumption of yellow
turmeric (Curcuma longa) supplement were identified in Scandinavian countries [14]. Further investigations identified the compound Nimesulide, a non-steroidal anti-inflammatory,
present in the HDSs as the precipitating cause of drug-induced liver injury (DILI) in these
cases [14]. The incidence of HDS-induced liver injury is increasing and is associated with
the rise in HDS use. Of the DILI cases in the US, 20% are related to HDS-induced liver
injury, and many of these cases are related to HDSs containing more than one dietary
ingredient [10]. The HDSs that are the most associated with DILI include those marketed
with appearance- and performance-related claims [13].
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Before HDS consumption, the FDA recommends that consumers reach out to their
healthcare providers to discuss safe use [11]. HDSs often contain more than one dietary
ingredient that can result in unintended interactions and adverse events. HDSs can also
impact the pharmacokinetics of prescription drugs, resulting in unintended HDS–drug
interactions [11]. Under the Dietary Supplement and Nonprescription Drug Consumer
Protection Act of 2006, individual HDS manufacturers are responsible for reporting serious
adverse events that can be attributed to HDS consumption to the FDA [15]. Many of the
serious adverse events reported to the FDA occurred in HDSs containing multiple dietary
ingredients [16].
3. Hepatotoxic Effects
The liver is involved in many bodily processes, including endocrine and exocrine
functions, immunologic functions, and a wide range of metabolic functions, such as the
breakdown of carbohydrates, fats, and proteins. One of the liver’s exocrine functions
involves bile production, a mixture of bile acids, water, phospholipids, cholesterol, and
electrolytes. Many drug metabolites rely on bile as a route of excretion. The liver also aids
the production of albumin; clotting factors; amino acids; and urea, made from ammonia,
which the liver transaminases and deaminates from amino acids [17].
Many molecules in the bloodstream are eliminated by the liver’s two-phase biotransformation and elimination system. Phase I, known as hydroxylation, includes various
Cytochrome P450 enzymes that add reactive oxygen sites to these target molecules. Phase II
involves various conjugation enzymes that add water-soluble groups to aid in elimination.
Foods and nutrients have been shown to be necessary for and able to modulate this system.
Phase 1 cytochrome enzymes transform their starting molecules via oxidation, peroxidation,
and reduction reactions by adding hydroxyl, carboxyl, and/or amino acid groups to their
starting molecules. These reactions create electrophilic molecules that have the potential to
injure their surrounding structures. Cytochrome phenotypes and numbers vary between
different people, meaning that their ability to handle certain drugs and nutrients via this
pathway may differ significantly. This variation can affect drug efficacy, side effect profiles,
and toxicity [18].
Phase 1 enzymes: CYP1 enzymes are involved in processing hormones, various pharmaceuticals, procarcinogens, polycyclic aromatic hydrocarbons, and other environmental
toxins. CYP2A-E enzymes are involved in processing ketones, glycerol, fatty acids, drugs,
xenobiotics, and hormones and have been shown to have several phenotypes that affect
drug metabolism. CYP3A enzymes are involved in processing caffeine, testosterone, progesterone, androstenedione, and polyaromatic hydrocarbons. CYP4 enzymes are primarily
found outside of the liver and play a smaller role in drug processing. The phase 1 enzymes
and their substrates are outlined in Table 1 below [18].
Phase 2 enzymes: UDP-glucuronosyltransferases are essential in processing steroid
hormones and bilirubin. These enzymes covalently link glucuronic acid to their target
molecule. Sulfotransferases transfer a sulfuryl group to their target molecule, which often
reduces their target molecule’s reactivity and toxicity. Glutathione S-Transferases are
enzyme complexes that transfer a glutathione group to their target molecules and are
induced when reactive oxygen species are being created. Amino acid transferases transfer
an amino acid to their target molecule to aid in elimination. N-acetyl transferases transfer
acetyl groups to their target molecules. Methyltransferases methylate their target molecules
and play a vital role in estrogen detoxification. The phase 2 enzymes and their substrates
are outlined in Table 2 below.
Other Pathways: Nrf2 is a transcription factor that helps to regulate detoxification
and antioxidant systems. When activated, Nrf2 dissociates from the cytosolic protein and
translocates into the nucleus to promote phase II detoxification enzymes. NrF2 is protective
against stress-related conditions and toxicity from drugs or herbals. Metallothionein is also
a key regulator with the ability to regulate heavy metal detoxification. The cysteine rich
protein is regulated by certain stimuli such as heavy metals, oxidative stress, and zinc. In
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certain conditions, such as inflammatory bowel disease, metallothionein has shown to be
decreased in intestinal mucosa [18].
Mechanisms for liver injury resulting from HDSs can come in several forms. Anabolic
steroids, which are sometimes marketed as “bodybuilding supplements,” can cause injury
to the liver via a cholestatic mechanism, leading to increased bilirubin levels and, in some
cases, jaundice and itching [10]. Green tea extract (GTE), along with many other HDSs,
has an unknown liver injury mechanism but causes a pattern of transaminitis similar to
that of the liver injury caused by acute hepatitis [10]. Liver biopsies in patients with acute
liver injury related to GTE use may show eosinophils, inflammation, and necrosis in a
pattern similar to the one induced by acute hepatitis [19]. Multi-ingredient nutritional
supplements (MINS) often include several ingredients, and toxicity can be caused by
a specific component of the regimen or an unknown adulterant, making it difficult to
determine the mechanism of injury [10].
Recent data have suggested that liver injury is immune mediated by haptenization or
via molecularly mimicry and that certain drugs’ reactive metabolites may stress hepatocytes
to stimulate the adaptive immune system by binding to proteins, which further stimulate TCells to express Fas ligand (FASL) and tumor necrosis factor (TNF) to induce cell death [20,21].
Table 1. Cytochrome P450 enzymes that add reactive oxygen sites to these target molecules, creating
more electrophilic compounds.
Phase 1 Enzymes
CYP Family

Typical Substrates

CYP1

Hormones, various pharmaceuticals, procarcinogens, polycyclic aromatic
hydrocarbons, and other environmental toxins.

CYP2A–E

Ketones, glycerol, fatty acids, drugs, xenobiotics, and hormones.

CYP3A

Caffeine, testosterone, progesterone, androstenedione, and polyaromatic
hydrocarbons.

Information cited from Hodges, R.E.; Minich, D.M. (2015) [18].

Table 2. Conjugation enzymes that add water-soluble groups to aid in elimination.
Phase 2 Enzymes
Phase 2 Enzyme Class

Group Phase 2 Enzyme Adds to Target

UDP-glucuronosyltransferases

Glucuronic acid

Sulfotransferases

Sulfuryl

Glutathione
S-Transferases

Glutathione

N-acetyl transferases

Acetyl

Methyltransferases

Methyl

Information cited from Hodges, R.E.; Minich, D.M (2015) [18].

4. Genetic and Demographic Susceptibility
The number of patients who suffer from DILI caused by HDSs is difficult to determine,
as it is often unclear if patients are using these substances. However, there are data
estimating that HDSs are responsible for 20–40% of acute liver failure (ALF) cases due to
DILI. A Chinese study of 26,000 cases of DILI showed that only 1% of cases associated with
HDSs led to ALF, but of the patients who died from ALF, HDSs were the leading cause [22].
The authors of this review investigated the demographics of patients with DILI caused
by HDSs in Europe, Asia, and the US. They concluded that the typical clinical patient
presentation was a young, otherwise healthy female presenting with elevated bilirubin and
aminotransferases [22]. DILI in patients using HDSs for bodybuilding usually presents
with increased bilirubin and prolonged jaundice in young men. Hepatocellular DILI leads
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to higher rates of death and transplantation and predominantly presents in middle-aged
women [23].
Differences in cytochrome P450 genetic polymorphisms affect drug metabolism and
have been linked to the accumulation of toxic drug or metabolite levels, suggesting a
genetic predisposition to developing hepatotoxicity [24].
Multi-ingredient products are increasingly implicated as causes of acute liver injury;
green tea is a common ingredient in these products [25]. The US Drug-Induced Liver Injury
Network (DILIN) performed a formal causality assessment on over 1400 patients who
suffered from liver injury. Patients with green tea liver injury were often jaundiced and
symptomatic and had elevated levels of serum aminotransferase with a hepatocellular
pattern of injury [23]. They also had mildly elevated alkaline phosphatase levels. In patients
with green tea-associated liver injury, HLA typing showed HLA-B*35:01 in 72% of cases.
This type was only found in 15% of liver injury cases due to other supplements and in 12%
of cases where the injury was the result of other drugs. These differences were statistically
significant [25].
5. Pharmacokinetic and Pharmacodynamics Changes in Chronic Liver Disease
Liver disease can affect pharmacokinetics in many ways. Liver blood flow and enzyme
activity are both crucial to metabolize drugs. Some drugs with a high first-past metabolism
are affected by changes in liver blood flow, while drugs with “low hepatic extraction” are
more affected by hepatic failure [24]. Plasma proteins are also important to pharmacokinetics and can be affected by liver function [26]. Liver impairment also has the potential to
affect drug availability, distribution, and biliary elimination [27].
Patients with chronic liver disease (CLD) may have a slower metabolism in the liver,
as their ability to metabolize proteins depends on their current hepatic reserve. Patients
with CLD are also more likely to have low serum albumin and elevated serum ammonia
levels and suffer from zinc deficiency at a higher rate, which decreases the capacity for
ornithine transcarbamylase to metabolize ammonia [28]. As liver disease progresses to
cirrhosis, the liver loses more function. Loss of liver parenchyma decreases the number
of enzymes that are active in drug metabolism. In patients with cirrhosis, cytochrome
alterations can occur. These changes are variable with different comorbid conditions and
the state of current disease progression. However, there is a general pattern in patients with
cirrhosis that CYP1A and CYP31 concentrations decrease while levels of CYP2C, CYP2A,
and CYP2B remain at their baseline concentrations. Alcohol and aldehyde dehydrogenase
levels may also be affected. Sulphation rates may decrease as well, but glucuronidation
reactions are mostly unaffected by cirrhosis [29].
Studies have shown that various nutrients and HDSs, including cruciferous vegetables,
resveratrol, green tea, black tea, curcumin, turmeric, soybean, garlic, fish oil, rosemary,
astaxanthin, and chicory root, are inducers of CYP1 enzymes [18]. CYP1 enzyme inhibition
has been found in black soybean, black tea, turmeric, apiaceous vegetables, quercetin,
daidzein, grapefruit, peppermint, dandelion, kale garlic, and chamomile [18]. Inducers of
CYP2 enzymes may include chicory root, quercetin, rosemary, garlic, and fish oil. Their
inhibitors may include ellagic acid, green tea, turmeric, black tea, resveratrol, myricetin,
watercress, chrysin, and medium-chain triglycerides [18]. Nutrients that induce CYP3
enzymes may include garlic, fish oil, rooibos tea, and turmeric. Inhibitors may include
green tea, black tea, quercetin, grapefruit, myricetin, kale, and soybean. Inducers of CYP4
enzymes may include green tea and the caffeic acid found in coffee [18].
6. Interaction with Other Drugs
There are concerns regarding pharmacokinetic interactions between HDSs and conventional medication with the same absorption, distribution, metabolism, or excretion mechanisms. CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, OATP1A1, OATP1A2,
OATP2B1, and P-gp are the most well categorized to date. The six CYP enzymes account
for the metabolism of approximately 80% of all prescribed drugs (Zanger UM, Schwab
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M). In terms of drug metabolism, cytochrome P450 enzymes regulate gene expression
and enzyme activities and impact genetic variation [30]. Two common HDSs that affect
drug metabolism are goldenseal and St. John’s wort. The drugs that are most affected
and contraindicated due to concomitant use with St John’s wort are metabolized via the
CYP3A4 and P-glycoprotein pathways [31]. Specifically, St. John’s wort may reduce the
effectiveness of cyclosporine (Sandimmune), tacrolimus (Prograf), warfarin (Coumadin),
protease inhibitors, irinotecan (Camptosar), theophylline, digoxin, venlafaxine, and oral
contraceptives; one should avoid combining St. John’s wort with over-the-counter and
prescription medications [31].
7. Clinical Diagnosis and Management
7.1. Clinical Diagnosis
Due to HDS-induced hepatotoxicity, a wide range of clinical presentations and a lack
of objective diagnostic tests make it difficult for providers to establish an early diagnosis and begin early management. Patients will present with scleral icterus, abdominal
pain/discomfort, nausea/vomiting, pruritus, or choluria [10]. DILI is a diagnosis of exclusion. To make a final diagnosis of DILI, a provider must obtain a detailed history and
exhaust alternative diagnoses with a comprehensive work-up to distinguish competing
etiologies [10].
7.1.1. Classifications
The Roussel Uclaf Causality Assessment Method (RUCAM), introduced in 1993, was
developed to quantify the strength of association between liver injury and the medication
implicated as causing the injury [32]. When it was validated, the scale demonstrated 86%
sensitivity; 89% specificity; and positive and negative predictive values of 93% and 78%,
respectively [32]. The scale results were reproduced by four experts after a positive rechallenge by applying RUCAM to 50 suspected DILI cases. During the experts’ reproduced
assessment, they found an accuracy of 99%, 74%, and 37%, respectively, which indicated a
major discrepancy between expert raters [32–34]. Flaws in the scale are due to the need to
assess verifiable case information, long follow-up data, and the inability to discriminate
between contaminant drugs [35].
RUCAM was later modified by Maria and Victorino. This modification, the M&V scale,
incorporates extrahepatic disease manifestations [36]. The overall score corresponds to five
probability degrees: definite, probable, possible, unlikely, and excluded. The M&V scale
was validated using real and fictitious cases and was compared with the classifications
provided by three external experts. The comparison showed 84% agreement between the
scale and expert opinions [36]. However, the scale is limited by the number of identified
cases and unknown latency periods [36–38].
The Revised Electronic Causality Assessment Method (RECAM) is a superior update
to RUCAM. It underwent 12 versions based on iterative testing, and the final scoring
between RECAM and RUCAM was conducted on 98 DILIN and 96 Spanish DILI cases. RECAM had better overall agreement with expert opinion and better discriminate diagnostic
categories [36].
7.1.2. Hy’s Law
Hy’s law is based on the observational work of Hy Zimmerman [37]. Zimmerman’s
observations showed that pure hepatocellular injury is an indicator of potential DILI.
According to this observation, drug-induced jaundice caused by a drug or chemical that
induces hepatocellular injury leads to death or liver transplantation in >10% of cases [37].
The FDA includes three major components of DILI in their guidance to pharmaceutical
companies for the pre-marketing phase of drug safety evaluations [38]:
1.

The drug causes hepatocellular injury, demonstrated by a higher incidence of the
upper limit of normal ALT or AST that is three-fold greater than the (non-hepatotoxic)
control drug or placebo.
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2.
3.

Among trial subjects with AT elevations, one or more also show TBL serum elevations >2 × ULN without initial findings of cholestasis (elevated serum ALP).
No other explanation can be found for the increased AT and TBL, such as viral
hepatitis A, B, or C; preexisting or acute liver disease; or another drug capable of
causing the injury.

In a large population, two positive components are highly predictive that the drug has
the potential to cause severe DILI [38].
The FDA also follows a standard process to evaluate liver safety in large clinical
trials database using eDISH plot “evaluation of drug induced serious hepatotoxicity” [20].
eDISH provides a graphical representation broken down into four quadrants. The Temple
Corollary quadrant is defined as a rise in serum ALT >3 ULN but not a concurrent rise in
serum TBIL >2 × ULN [20]. This region suggests an increased risk of severe DILI.
7.2. Management
No data recommend a specific liver biochemistry monitoring plan when a potential
hepatotoxic agent is prescribed in individuals with known CLD. The gold-standard treatment for DILI is to withdraw the offending medication. However, in severe cases, liver
transplant will be indicated. Currently, there is no approved antidote for ALF resulting
from idiosyncratic DILI. For these reasons, liver tests should be monitored in patients who
are taking HDSs [31].
8. Drug-Induced Hepatotoxicity and Obesity
The increased incidence of drug induced hepatotoxicity in patients with obesity has
emerged in recent clinical trials. Obesity is often associated with heart disease, T2D,
hyperlipemia, non-alcohol fatty liver disease (NAFLD), and osteoarthritis. One of the
hallmark features of NAFLD is hepatic steatosis [39]. Some drugs may worsen obesityrelated NAFLD because of the increase in lipid deposition and necroinflammation [20].
Simultaneously, drug-induced liver toxicity may worsen due to a more hostile metabolic
environment because of the increased lipid deposition and necroinflammation. This harsh
metabolic environment is theorized to increase CYP2E1 expression/activity and reduce
MRC activity, thus leading to an increased inflammatory state resulting in DILI [40].
9. Common Hepatotoxic Agents on the HDS Market
9.1. Garcinia Cambogia
Garcinia Cambogia (GC), also known as garcinia gummi-gutta or Malabar tamarind,
is a fruit with origins in southeastern Asia. The rind is used to preserve and flavor food,
and GC extract has been used more recently for weight loss, with mixed evidence [39]. The
active component of GC, hydroxycitric acid (HCA), is associated with appetite suppression
due to its inhibition of the ATP citrate lyase and decreased fatty acid synthesis. GC is
commonly an ingredient in over-the-counter multi-ingredient dietary supplements (MIDS),
such as Hydroxycut and Vi-Trim, which has made it difficult to assess its toxicity alone.
However, studies in animal models indicate that there are no major toxicities aside from
testicular toxicity at high doses, and rare cases of serotonin syndrome, rhabdomyolysis,
and hepatic toxicity have been reported in humans [19,41].
Besides its involvement in decreased fatty acid synthesis, HCA has further downstream effects, such as increased lipid oxidation, and it may also suppress appetite via
decreased serotonin reuptake [42]. A study of mouse 3T3-L1 preadipocytes treated with
GC extract (59.55% HCA) found the suppression of MDI-induced adipogenesis and mitotic
clonal expansion via the modulation of p90RSK and Stat3 [43]. Several clinical trials with
GC alone or combined with other supplements in obese or overweight subjects reported
decreases in triglycerides, cholesterol, body weight, body fat, and/or in the visceral adiposity index [44–50]. However, a review of randomized, double-blind, placebo-controlled
trials evaluating GC alone found conflicting results regarding weight loss and identified
several weaknesses in the study designs [42]. An earlier meta-analysis of randomized,
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double-blind, placebo-controlled trials evaluating HCA alone found a borderline statistically significant decrease in body weight in HCA groups compared to the placebo groups,
but the effect size was small and had uncertain clinical relevance [51]. Thus, there is a lack
of robust evidence to support the use of GC as an effective weight loss supplement.
GC has been implicated in several reports of liver injury; the first case of fulminant
hepatic failure from “purified” GC extract was published in 2016 [24]. Vuppalanchi et al.
identified five cases of liver injury from GC alone that were reported in DILIN from
2004–2018. The liver injury pattern was hepatocellular in four cases and mixed in one case.
All the patients were hospitalized, and one required a liver transplant. The number of days
from the start of drug consumption to the onset of liver injury ranged from 35 to 139. When
combined with green tea or ashwagandha, there were 22 cases of liver injury associated
with GC. There were no significant differences in the clinical characteristics or outcomes
between the cases related to GC alone and the cases of GC with green tea; both groups
presented with acute hepatitis [52]. Since 2019, there have been at least five case reports
of liver injury associated with weight-loss supplements containing GC [53–57]. GC has a
DILIN category B likelihood score (likely rare cause of clinically apparent liver injury), with
a frequency of <1:10,000 for hepatic adverse reactions. The exact mechanism of hepatotoxicity is unknown; it appears to be idiosyncratic and generally resolves 1–3 months after
discontinuation [41]. HCA increases hepatic collagen accumulation and lipid peroxidation,
and it is involved in inflammatory responses and oxidative stress, which may lead to
hepatocellular injury [58].
9.2. Saw Palmetto
Serenoa repens, commonly known as saw palmetto (SP), was the 11th highest selling
herbal supplement in the US in 2020 [59]. This supplement is derived from the berries of
a palm-like plant that is native to Florida, and the southeastern US SP supplements are
available in a variety of forms, including dried berries, powdered capsules, tablets, liquid
tinctures, and liposterolic extracts. In 2020, global SP supplement sales totaled over USD
117 million.
SP supplements are mainly used to improve urinary symptoms related to benign
prostatic hyperplasia (BPH), although there are not sufficient randomized controlled studies
in human subjects to conclude its claim [58]. The mechanism of action for SP is not well
understood. Many believe that it works through inhibiting 5α-reductases and that it
may also have other anti-androgenic and anti-inflammatory effects [60]. Studies have
demonstrated that SP has α1-adrenoreceptor inhibitory effects [61]. Studies on rat models
have shown that SP works on the α1-adenoreceptors and muscarinic receptors in the lower
urinary tract to relieve dysuria symptoms [62]. However, multiple double-blind RCTs have
shown no significant improvements in urinary symptoms using SP versus a placebo [63,64].
SP supplements are also used to treat alopecia and hair loss. The mechanism behind
this is thought to be related to SP’s antiandrogenic properties. Several RCTs have shown
reductions in hair loss and improvements in hair quality using SP supplements [57,63,64].
SP supplements have also been used to enhance sperm production, breast size, and libido
and may also function as a mild diuretic [65]. However, almost all current formulations
containing SP also contain other vitamins, minerals, or chemical additives, making it
challenging to discern the exact extent of SP’s contribution to observed clinical findings.
The most common side effects of SP supplements include headache, fatigue, abdominal
pain, nausea, vomiting, diarrhea, and decreased libido [66]. Studies have shown that SP
supplements do not affect the hepatic clearance of co-administered medications and have
not been linked to liver enzyme disturbances with long-term use [67,68]. Three cases of
acute liver injury that can be attributed to SP have been reported [68–70]. In each case, liver
function returned to baseline upon discontinuing the supplement. SP has been linked to
acute pancreatitis in two separate case reports [71,72].
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9.3. Ashwagandha
Ashwagandha is an Ayurvedic herb derived from the roots of Withania somnifera,
which is an evergreen shrub found in India and Southeast Asia. For centuries, it has
been used in Ayurvedic medicine, but its use as an herbal supplement in the US has
increased in recent years [73]. The mainstream channel sales of ashwagandha totaled nearly
USD 11 million in 2019, a 45.2% increase from 2018, and it was the fifth highest selling
herbal supplement in the US Natural Channel [74]. Ashwagandha’s purported benefits
include increased energy, reduced fatigue, and anti-inflammatory effects, and it is used for
conditions such as stress, skin diseases, diabetes, arthritis, and epilepsy [73].
Clinical trials have demonstrated various effects of ashwagandha, such as improved
sleep quality [75–77]; improved cognitive performance [78], quality of life, and mental
alertness [76] in elderly subjects; decreased HAM-A scores in subjects with anxiety [79,80]
and high stress [81]; increased VO2max in healthy adults and athletes [82,83]; decreased
Perceived Stress Scale scores and serum cortisol in stressed adults [78,82,84]; and improved
depression and anxiety scores [85] and Perceived Stress Scale scores [86] in individuals with
schizophrenia or schizoaffective disorder. Due to its stress-reducing effects, ashwagandha
is considered an adaptogen, a substance that helps the body respond and adapt to stress
and environmental changes [84]. However, external validity, experimenter bias, publication
bias, lack of follow of follow up and poor study designs limit reported benefits.
There are few adverse effects associated with ashwagandha, although several cases
of mostly mild-to-moderate liver injury in patients taking commercial herbal products
containing ashwagandha have been reported in recent years [73]. A case series reviewed
five cases of cholestatic or mixed liver injury from 2016 to 2018 that were accompanied
by jaundice, pruritus, and hyperbilirubinemia [87]. Symptoms occurred 2–12 weeks after
starting the supplement, and liver tests normalized within 1–5 months of stopping use.
The one biopsy that was performed showed acute cholestatic hepatitis, and liver failure
did not occur in any of the cases. Since then, several more reports of ashwagandha-related
liver injury have emerged [88,89], with one case of ALF requiring transplantation [90].
The patient in this case however was also taking an unknown dose of progesterone; thus,
it is unclear whether this drug also played a role in the development of ALF. This case
and one of the other cases showed a hepatocellular injury pattern that contrasted the
previously described cholestatic or mixed patterns. Ashwagandha has a DILIN category
C likelihood score (probable cause of clinically apparent liver injury). Its mechanism of
hepatotoxicity is unclear, although the metabolite withanone appears to form adducts with
several nucleosides, DNA, and amines and thus may cause DNA damage in low-GSH
conditions [91]. Research in rats suggests that Withania somnifera has a hepatoprotective
effect that is caused by decreasing ALT, AST, ALP, MDA, and bilirubin and increasing the
antioxidant capacity [92].
9.4. Green Tea
Green tea is produced from the leaves of the Camellia sinensis plant, which is found
primarily in South and Southeast Asia. It is unfermented, which preserves its antioxidant
polyphenolic catechols. Tea catechins are the bioactive phytochemicals responsible for the
antioxidative properties of green tea, with (−)-epigallocatechin-3-gallate (EGCG) being the
most abundant, active, and hepatotoxic species [93]. GTE contains a concentrated amount
of these substances. Increased production and a rising demand have increased GTE use
in recent years [7]. Interest in the antiviral activity of EGCG also increased during the
pandemic, as people considered its use against SARS-CoV-2 [94]. In 2020, consumers in the
US spent over USD 31.4 million on green tea HDSs [7].
The proposed benefits of green tea stem from its antioxidant activity; low incidence
of high-oxidative-stress pathologies such as cardiovascular disease and cancer; and its
potential to improve the metabolism of glucose, lipids, and uric acid [95]. Green tea has been
marketed for a variety of conditions, from cancer prevention to weight loss, with varying
scientific support [96]. Green tea accounts for more than 20% of global tea production,
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and GTE is frequently used in HDSs [97]. GTE is the main ingredient in heavily marketed
over-the-counter weight-loss supplements such as Slimquick, Hydroxycut, Herbalife, the
Right Approach, and Ripped Fuel. GTE formulations and concentrations vary amongst
different HDS products. While consuming green tea on its own is relatively innocuous, it is
the consumption of GTE that is a cause for concern.
Given its increasing popularity, it is important to define the safety profile of GTE.
although rare, GTE has been linked to more than 100 reports of characteristic acute hepatitislike illness, which presents with acute hepatocellular injury and jaundice [98]. It has a
DILIN category A likelihood score, indicating that it is a well-established cause of clinically
apparent acute liver injury, usually arising within 1 to 6 months of starting the product
and resolving within 1 to 2 months after stopping use [98]. Recurrence is possible upon
re-exposure, and the aminotransferases, alkaline phosphatase, and bilirubin levels react
accordingly. The use of the weight loss supplement Slimquick has led to fulminant liver
failure and orthotopic liver transplantation in some cases, while fatal instances have been
reported in up to 10% of cases [10,99]. However, there is a dearth of research regarding
GTE’s effects in different populations. Considering the wide range of injuries, it is necessary
to explore the circumstances that lead to these adverse effects. Specific genes in mice were
found to be associated with susceptibility to EGCG toxicity, and analogous human genetic
variants may show the same relationship [1].
GTE’s potential for therapeutic benefits must be weighed with its risk of hepatotoxicity.
This balance is illustrated in the treatment of cirrhosis caused by chronic hepatitis C
virus (HCV) infection. In one prospective, randomized, double-blind study involving
338 Japanese patients, cyanidanol appears to have increased host anti-HBV responses
and improved host clearing of infected hepatocytes [100]. While patients may benefit
from the antiangiogenic, antioxidant, and antifibrotic properties of EGCG, the reported
dose-dependent potential for hepatotoxicity could be further augmented in cases in which
cirrhosis is present [101]. However, further clinical studies must be investigated.
Recently, with a rise in obesity, GTE consumption has been investigated in comparison
to fasting and fad states. The study showed that EGCG caused dose-dependent hepatotoxicity in mice under dietary restriction, suggesting a combination of effects of dietary
restriction and EGCG. It was hypothesized that the disturbance of lipid metabolic pathways
from dieting and the disruption of the Lands’ cycle led to liver injury. However, these
studies were limited to animal trials [102]. There are few clinical studies in human subjects,
and further investigation is necessary.
9.5. Aloe Vera
Aloe vera is a cactus-like plant in the lily family that is used both topically and orally.
Aloe vera products come from the leaf and contain a wide range of substances such as
anthraquinones; vitamins A, C, and E; enzymes; salicylic acid; and hormones. Topical
creams that include aloe are used for cosmetic purposes and wound healing, and its extracts
are used for food flavoring and in dietary supplements. Mainstream channel aloe vera sales
totaled USD 21 million in 2019, and it became the sixth highest selling herbal supplement in
the US Natural Channels [74]. Aloe vera is purported to aid in weight loss and in conditions
such as arthritis, asthma, chronic fatigue, dyspepsia, constipation, and skin ailments.
Furthermore, the antiproliferative, anti-inflammatory, and hepatoprotective effects of aloe
vera have been indicated in several animal and in vitro studies [103]. Hepatoprotective
effects have been demonstrated in mice with acetaminophen-induced hepatitis [104] and
in rats with non-alcoholic steatohepatitis [105], ischemia-reperfusion injury [106], alcoholinduced hepatic damage [107], and oxidative stress-induced damage [108].
There are no major adverse effects associated with topical aloe vera aside from rare
hypersensitivity reactions, skin rash, and allergic dermatitis. However, oral preparations
have been associated with at least a dozen cases of liver injury since 2005. The pattern
of liver injury was primarily hepatocellular and had a presentation similar to acute viral
hepatitis [103]. A review of nine cases of aloe vera-induced liver injury found a latency that
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ranged from 2 weeks to 6 months, and the majority had a probable RUCAM score [109].
The overall pattern in the six liver biopsies that were performed indicated portal and acinar
inflammatory cell infiltration with bridging necrosis and bile stasis [109]. A systematic
review of herb-induced liver injury identified 22 cases associated with aloe vera, in which
4.1% were treated with liver transplantation, 4.7% were treated with chronification, and 9.5%
resulted in death. However, liver transplantation and death occurred in patients consuming
multiple herbs. The injury was generally self-limiting and resolved after stopping aloe vera
consumption, with n liver tests typically normalizing within 50 days [110].
The hepatic injury caused by aloe vera appears to be idiosyncratic; none of the individual components of the leaf extracts are known to be hepatotoxic [103]. In one study,
healthy volunteers consumed 2 oz of aloe vera gel twice daily for 60 days, and no changes
in the biochemical indices of liver function, ultrasound markers of hepatic blood flow,
or liver tissue elasticity were found [111]. Liver injury from aloe vera may be related to
hypersensitivity, as eosinophilic infiltrates were noted in several biopsies [109].
9.6. Germander
Teucrium chamaedrys, an herb commonly called germander, has been used for many
years to treat gastrointestinal illness, fevers, gout, and other forms of inflammation. More
recently, it was marketed to address weight loss and elevated cholesterol; however, studies
on these effects are lacking [19]. Germander has been identified as a likely cause of acute
liver injury and is associated with several cases of ALF necessitating transplant [19]. Most
cases of acute liver injury resolve once germander supplementation is stopped, but some
patients have died from ALF caused by germander [19]. Latency of acute liver injury
for germander averages around 9 weeks but can take as little as 2 weeks or as long as
18 weeks. Patients with germander-induced liver injury present with many similarities
to a case of acute viral hepatitis including nausea, jaundice, and a hepatocellular pattern
of liver enzyme elevation. Liver biopsies showing centrilobular necrosis were found in
patients suffering from this acute germander liver injury [19]. Germander has also been
associated with a presentation similar to chronic hepatitis when taken over the course
of months. The symptoms of this more chronic presentation may include arthralgias
and fevers, while serum tests may show autoantibodies. Fibrosis was seen on biopsies
in these cases [19]. Germander contains neoclerodane diterpenoids, whose metabolites
are the probable cause of its hepatotoxicity. Neoclerodane diterpenoids use CYP450 for
metabolism, creating metabolites that deplete glutathione, attach to proteins, and interfere
with many other cellular activities. Similar to acetaminophen, this substance harms the
liver with a mechanism that depletes glutathione. Hepatotoxic effects recur in many cases
when patients are again exposed to germander [19].
9.7. Vitamin A
Vitamin A is a fat-soluble molecule that is a dietary requirement for normal functioning
of the eyes, skin, bones, and immune system. It has a recommended daily allowance (RDA)
of between 700 and 900 µg per day in adults and can have toxic effects when people take
amounts that are significantly higher than their daily allowance. Vitamin A has a DILIN
likelihood score of A, the highest score on this scale, indicating that it is a well-known cause
of liver injury [19]. It is often taken in the form of a pill, tablet, or a solution but may also be
found in many vitamin and mineral combinations and herbal supplements [19]. Vitamin
A is also indicated and often prescribed to treat measles, xeropthalmia, and malnutrition,
and is sometimes given to pregnant women to make sure they are not deficient [112].
Hepatotoxicity arises with the surreptitious use of vitamin A, not under a provider’s
guidance. Signs of toxicity include hepatosplenomegaly, jaundice, portal hypertension,
and liver injury. Toxicity can be acute or chronic in nature depending on how the vitamin
A is ingested. Acute cases can happen within a matter of days of large-dose ingestion,
while chronic cases may take many months to develop. Treatment involves discontinuing
supplementation and starting a low vitamin A diet [112].
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9.8. Black Cohosh
Black cohosh (BC) is often used to help mitigate menopause symptoms and has been
shown to be effective for this in some clinical trials [19]. Products labeled as BC have been
associated with liver injury, ranging from mild transaminases to cases of autoimmune
hepatitis, ALF, and death [19]. The mechanism of action is not fully understood, but it
is theorized to be an immunologic reaction. BC has well-established causes of clinically
apparent liver injury, giving it a likelihood score of A. It is difficult to isolate a cause in
these cases because many HDSs contain adulterants or mislabeled products. Most cases
improve with discontinuation of the HDS, but steroids or immunosuppression may be
needed in cases with long lasting autoimmune symptoms [19].
9.9. Turmeric
Turmeric comes from the roots of Curcuma longa, a ginger family plant native to India
and grown in southern Asia and central America [19]. In addition to its use as a dye and
spice for curry, turmeric and its purified extract curcumin are used in Ayurvedic medicine
to treat gastrointestinal issues and upper respiratory infections due to their potential antiinflammatory, antineoplastic, and antioxidant effects [19]. Specifically, curcumin decreases
proinflammatory cytokines; induces heme oxygenase-1 expression and reduced glutathione
synthesis; and regulates numerous antioxidant signaling pathways [113].
Prior to the recent publication of case reports of turmeric-associated liver injury,
turmeric had been known to temporarily increase serum enzymes without symptoms or
clinically apparent acute liver injury [19]. Curcumin has been investigated as a hepatoprotective agent and potential treatment for oxidative associated liver diseases, with two
clinical studies showing efficacy in NAFLD but lacking histological endpoints [113–115].
Another RCT found that lifestyle modifications plus curcumin significantly reduced hepatic
fibrosis and steatosis scores, but these changes were not significantly different from the
placebo group [116].
The emergence of cases of turmeric-associated liver injury may be attributed to the
introduction of high bioavailability turmeric via piperine (from black pepper) or nanoparticle delivery [19]. A systematic review and meta-analysis published in 2020 described seven
cases of acute hepatitis in Tuscany, Italy, from 2018–2019 associated with dietary supplements containing Curcuma longa, and it identified 23 other cases from 13 case reports in
multiple countries [117]. All cases in Tuscany involved high bioavailability formulations,
especially with piperine, which increases curcumin absorption by 200% [117]. Six of the
seven patients were female, and the age range was 45–68 years. ALT and AST were >1000
in six out of seven and five out of seven cases, respectively; the daily dose was 1000 mg or
greater in four out of seven cases. Positive dechallenge occurred in five out of seven cases,
and six of the seven cases had RUCAM and WHO-UMC categories of probable or possible
(1 unlikely/not assessable). All but one of the thirteen studies in the systematic review
mentioned the concomitant use of other medications/products, and positive dechallenge
was observed in 17 of 23 cases.
The pattern of liver injury is hepatocellular and presents similarly to autoimmune
hepatitis clinically and histologically [19]. Turmeric has a DILIN category B likelihood
score (likely rare cause of clinically apparent liver injury) [19]. The mechanism of liver
toxicity is not well understood and may be idiosyncratic; it is likely not an immunological
reaction [117]. Interaction with other drugs may also play a role in turmeric-associated
liver injury [117].
Summary of 9 common hepatotoxic HDSs on the market with their theoretical benefits
(Figure 1).
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of multiple case reports that have reported herbal induced liver injury. However, case

reports carry major limitations such as establishing a cause–effect relationship, danger of
over-interpretation, and publication bias [118].
Table 3. List of individual studies and their limitations.
Study

Claim

Major Limitation

Feng et al., 2021 [3]

Zinc sulfate shortens the duration of olfactory
dysfunction in patients with COVID

Low quality of selected trials; only RCTs were
included and had a wide variation with the targeted
population, mode of delivering HDS, outcomes, and
follow-up periods

Lunsford et al., 2016 [24]

Fulminant hepatic failure caused by Garcinia
Cambogia 5:1 extract

No independent laboratory evaluation of
supplement to identify contaminants/verify
composition

Han et al., 2021 [43]

Garcinia cambogia
extract suppresses adipogenesis in mouse 3T3-L1
preadipocytes via modulation of p90RSK and Stat3

In vitro study

Maia-Landim et al., 2018 [44]

Garcinia cambogia and Glucomannan reduce weight
and improve lipid and glucose blood profiles in
overweight/obese individuals

Not randomized; combination therapy with GC and
Glucomannan; included patients with dyslipidemias,
hypertension and type 2 diabetes receiving treatment
for 2 months to 4 years before study onset

Livers 2022, 2

132

Table 3. Cont.
Study

Claim

Major Limitation

Chong et al., 2014 [45]

IQP-GC-101 reduces body weight and body fat mass in
overweight Caucasian adults

IQP-GC-101 includes 4 different extracts including
GC; did not exclude subjects with regular caffeine
intake; no strict control of daily caloric intake

Vasques et al., 2014 [46]

Short-term Garcinia cambogia treatment significantly
reduces triglyceride levels in obese women without
affecting anthropometric
or calorimetric parameters

Small sample size; did not use intention-to-treat
methods; did not describe dropouts; did not include
p values for all comparisons

Vasques et al., 2008 [47]

Garcinia cambogia
plus, Amorphophallus konjac treatment significantly
reduces total cholesterol and LDL-c levels in patients
with obesity compared to placebo without affecting
anthropometric
or calorimetric parameters

Combination therapy with GC and Amorphophallus
konjac is relatively small sample size.

Toromanyan et al., 2007 [48]

Slim339 significantly reduces body weight in
overweight and obese individuals

Slim339 contains 5 extracts and calcium
pantothenate; relatively small sample size and short
treatment period

Opala et al., 2006 [49]

Botanical extract-based weight loss formula produces
significant change in the Body Composition
Improvement Index and decrease in body fat in
healthy, overweight subjects

Two different tablets with different combinations of
herbal extracts (GC in one tablet); % body fat
estimated with 4-skinfold method; more female than
male subjects (77 vs. 21); smoking not in exclusion
criteria (but monitored)

Tallei et al., 2021 [94]

Green tea extract may serve as a potential treatment
against COVID-19

In vivo studies have not been studied.

Peluso et al., 2017 [95]

The consumption of green tea can modulate the
antioxidant capacity of individuals

No convincing evidence from long-term intervention
studies in humans

Jurgens et al., 2012 [96]

Green tea preparations induce weight loss in
overweight or obese adults

Some studies had incomplete reporting and short
study period (12 weeks)

Whitsett et al., 2014 [99]

Case report of fulminant liver failure and orthotopic
liver transplantation in a patient after Slimquick use

Danger of over-interpretation and publication bias.
Not a powered clinical trial.

Isbrucker et al., 2006 [102]

EGCG caused dose-dependent hepatotoxicity in mice
under dietary restriction

Studies were limited to animal trials

Peng et al., 2016 [119]

Eight randomized studies with 800 patients and
showed positive effects on the levels of ALT, AST, TC
and TG, LDL.

Limited to the duration of follow up and small
sample size to confirm the efficacy and safety of the
study

Deshpande et al., 2020 [75]

Ashwagandha Improved sleep quality in meta-analysis

Short trial period to establish long term effects,
limited trials presented with a potential risk of
publication bias

Dimpfel et al., 2020 [78]

Ashwagandha Improved cognitive and concentration
performance

Insufficient details regarding preparation of the
extract, treatment administration, and randomization
procedures

Hoogenboom et al., 2020 [111]

hepatic injury caused by aloe vera appears to be
idiosyncratic; no changes in the biochemical indices of
liver function

Not all participants completed the trial, few missed
doses for some participants, trial lasted 60 days, low
number of participants

11. Conclusions
Considering increased HDS popularity and sales, it is crucial for clinicians to challenge
their use. With many hypotheses, conflicting data, and increased speculation, it is imperative for researchers to fill in the gaps of our current knowledge of HDS hepatotoxicity.
Although there is potential for hepatotoxicity, some studies have suggested different
outcomes. Certain herbal supplements have shown promising effects, such as Salvia
Miltorrhiza Bunge. A meta-analysis of eight randomized studies with 800 patients showed
positive effects on the levels of ALT, AST, TC and TG, LDL, and the liver/spleen-computed
tomography ratio in patients with NAFLD [116,118,119]. However, the study was limited
to the duration of follow up and would require a larger sample of randomized clinical trials
to confirm the efficacy and safety of the study.
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Additional research on biomarkers can help validate new sensitive and diagnostic
testing for early cases. A recent study showed that pyrrolizidine alkaloids (PAs), which are
natural toxins synthesized from different plant species, are considered toxic but are widely
found in food and herbal products. PAs were found in herbal infusions containing comfrey,
green tea, and honey [120]. More recent studies have found three potential biomarkers (hsamiR-148a-3p, hsa-miR-362-5p, and hsa-miR-194-5p) in patients with PA-induced hepatic
sinusoidal obstruction syndrome (HSOS) [121]. Further studies in this area are warranted.
Nonetheless, there is a need for a more complete understanding of the hepatoxic
effects of HDSs in the general population and specifically in patients with CLD. The impact
of the hepatotoxic effects caused by HDSs continues to be unclear because many forms of
liver disease can be mimicked by drug-induced liver injury.
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